Business Enquiries 0845 330 7556     info@trbchemedica.co.uk

A new study shows OSTENIL® PLUS to be non-inferior to cross-linked HA injectable. At the recent World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) in Milan, Italy, R L Dreiser et al  presented a poster with the results of a prospective, randomised, double blind, controlled, parallel group, non inferiority study at 50 sites in France.

Click on the images below to read more.

Abstract

Poster

Share this post